Focused on therapies for rare genetic forms of obesity, the company develops and commercializes drugs targeting the melanocortin‑4 receptor (MC4R) pathway. Its lead product, setmelanotide (marketed as Imcivree), is approved for certain ultra‑rare obesity disorders, with additional clinical studies e...
3 members of Congress have disclosed 12 trades in Rhythm Pharmaceuticals Inc (RYTM), a Healthcare company. The buy/sell breakdown shows 10 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-12-07 | KATHERINE CLARK | sell | $1K – $15K |
| 2018-01-16 | Thomas R Carper | sell | $15K – $50K |
| 2016-02-15 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2014-10-29 | Thomas R Carper | buy | $15K – $50K |
| 2010-08-12 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2010-08-12 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2010-07-12 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2010-07-12 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2010-07-10 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2010-04-08 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2010-04-08 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2010-01-12 | MICHAEL T. MCCAUL | buy | $1K – $15K |